Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | PRMT3 | O60678 | 3/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.37 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6500692 | 0.87 | RAB9A (0.52) | NPC1RAB9ALMNAKDM4EALDH1A1 | |
| SCHEMBL6509241 | 0.85 | KMT2A (0.36) | NPC1RAB9AEPHX1PRMT3KDM4E | |
| SCHEMBL6502232 | 0.84 | KMT2A (0.50) | NPC1RAB9ALMNAKDM4EALDH1A1 | |
| SCHEMBL6498512 | 0.84 | NPC1 (0.40) | NPC1RAB9APRMT3CCR3 | |
| SCHEMBL6505116 | 0.83 | S1PR2 (0.39) | NPC1RAB9AEPHX1PRMT3LMNA | |
| SCHEMBL6504671 | 0.82 | EPHX1 (0.51) | NPC1RAB9AEPHX1KDM4EALDH1A1 | |
| SCHEMBL6503922 | 0.82 | EPHX1 (0.51) | NPC1RAB9AEPHX1KDM4EALDH1A1 | |
| SCHEMBL6502145 | 0.80 | NPC1 (0.50) | NPC1RAB9AKDM4EALDH1A1KMT2A | |
| SCHEMBL6387491 | 0.80 | KDM1A (0.39) | NPC1RAB9AALDH1A1CNR1KMT2A | |
| SCHEMBL6506411 | 0.80 | SMN1; SMN2 (0.44) | HTR3ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | NPC1 277/4885RAB9A 2649/4885EPHX1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.